[{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antibody-Based therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ BriaCell","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ BriaCell"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Harvard Medical School","highestDevelopmentStatusID":"2","companyTruncated":"BriaCell Therapeutics \/ Harvard Medical School"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Bria-Pros","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ University of Wisconsin\u2013Madison","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ University of Wisconsin\u2013Madison"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Caris Life Science","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Caris Life Science"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inycte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Inycte","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inycte"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"SV-BR-1-GM","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"NYCBS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ NYCBS","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ NYCBS"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by BriaCell Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
